The Russian pharmaceutical market is one of the most interesting worldwide.

In part, this is due to the fact that it is already one of the “top ten” today in an international comparison. There is also a two-digit growth rate that, according to forecasts, will lead to a quadrupling of the market volume by the end of 2020. However: In comparison with the German pharmaceutical market, the overall Russian market volume is still proportionally small. When comparing the countries and measured against the sale prices, it amounts to only a third. On average, Russians spend five times less on healthcare than Germans. The reasons for this are diverse. The lower average earnings, the widespread practice of self-treatments and the relatively poor health system are the primary causes. The driver for this nonetheless rapid growth is the 2020 Pharmaceutical Strategy Program that was started about five years ago by the Ministry for Industry and Trade. The goal of this program is the modernization of the pharmaceutical industry with the simultaneous improvement of healthcare for the Russian people. In order to make the domestic pharmaceutical industry “fit for purpose”, three instruments are used: the strengthening of the local production, the reduction of generic imports and the development of innovation. Today, attractive market conditions have resulted in new production operations being built by national and top international pharmaceutical companies such as Novartis, Astra Zeneca and Teva. There are three main pharmaceutical clusters, these are located in St. Petersburg, Kaluga and Yaroslavl. They are attractive due to favourable investment conditions, a comprehensive educational and research network and their infrastructure.

If Russia intends to cover half of its need for medications itself by the year 2020, the need for flexible packaging materials will also increase. As a result, Constantia Flexibles Pharma has been building upon the successful collaboration with the Russian company “TT print” for many years.